title: Structurally distinct hybrid polymer/lipid nanoconstructs harboring a type-I ribotoxin as cellular imaging and glioblastoma-directed therapeutic vectors.
abstract: A nanoformulation composed of a ribosome inactivating protein-curcin and a hybrid solid lipid nanovector has been devised against glioblastoma. The structurally distinct nanoparticles were highly compatible to human endothelial and neuronal cells. A sturdy drug release from the particles, recorded upto 72 h, was reflected in the time-dependent toxicity. Folate-targeted nanoparticles were specifically internalized by glioma, imparting superior toxicity and curbed an aggressively proliferating in vitro 3D cancer mass in addition to suppressing the anti-apoptotic survivin and cell matrix protein vinculin. Combined with the imaging potential of the encapsulated dye, the nanovector emanates as a multifunctional anti-cancer system.
authors.affiliation: Bio Nano Electronics Research Center, Graduate School of Interdisciplinary New Science Toyo University, Kawagoe, Saitama, 350-8585, Japan.
authors.forename: M Sheikh
authors.initials: MS
authors.lastname: Mohamed
authors.forename: Srivani
authors.initials: S
authors.lastname: Veeranarayanan
authors.forename: Ankur
authors.initials: A
authors.lastname: Baliyan
authors.forename: Aby Cheruvathoor
authors.initials: AC
authors.lastname: Poulose
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Nagaoka
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Minegishi
authors.forename: Seiki
authors.initials: S
authors.lastname: Iwai
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Shimane
authors.forename: Yasuhiko
authors.initials: Y
authors.lastname: Yoshida
authors.forename: Toru
authors.initials: T
authors.lastname: Maekawa
authors.forename: D Sakthi
authors.initials: DS
authors.lastname: Kumar
mesh_terms: D017209:Apoptosis / Q000187:drug effects; D001932:Brain Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D045744:Cell Line, Tumor; D003692:Delayed-Action Preparations / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology; D004354:Drug Screening Assays, Antitumor; D042783:Endothelial Cells / Q000378:metabolism / Q000473:pathology; D005909:Glioblastoma / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D006801:Humans; D051034:Inhibitor of Apoptosis Proteins / Q000378:metabolism; D008055:Lipids / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology; D057054:Molecular Imaging; D049329:Nanostructures / Q000737:chemistry*; D009363:Neoplasm Proteins / Q000378:metabolism; D009474:Neurons / Q000378:metabolism / Q000473:pathology; D054789:Ribosome Inactivating Proteins, Type 1 / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology; D000077022:Survivin; D016596:Vinculin / Q000378:metabolism
chemical_list: C107489:BIRC5 protein, human; D003692:Delayed-Action Preparations; D051034:Inhibitor of Apoptosis Proteins; D008055:Lipids; D009363:Neoplasm Proteins; D054789:Ribosome Inactivating Proteins, Type 1; D000077022:Survivin; C488955:VCL protein, human; C515388:curcin protein, Jatropha curcas; D016596:Vinculin
keywords: brain cancer; curcin; folate targeting; ribosome inactivating protein; solid lipid nanoparticles